Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 13/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065825 | 1.00 | S1PR1 (0.40) | S1PR1S1PR3S1PR5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2065315 | 0.82 | S1PR1 (0.38) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2066219 | 0.79 | S1PR1 (0.54) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2066218 | 0.79 | S1PR1 (0.54) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2064028 | 0.79 | S1PR1 (0.56) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2065671 | 0.77 | S1PR1 (0.44) | S1PR1S1PR3S1PR5ALDH1A1SMN1; SMN2 | |
| SCHEMBL27819337 | 0.77 | S1PR1 (0.38) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2065006 | 0.76 | S1PR1 (0.48) | S1PR1S1PR3 | |
| SCHEMBL884078 | 0.73 | S1PR1 (0.73) | S1PR1S1PR3S1PR5 | |
| SCHEMBL884079 | 0.73 | S1PR1 (0.73) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222667-B1 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-8148410-B2 | Thiophene derivatives as agonists of S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-04-03 | — | — | US | disclosed |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-14 | — | — | US | disclosed |
| EP-2222667-A2 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885S1PR5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.